Conversely, DPP-4 inhibitors for the treatment of diabetes mellitus (DM) were expected to have cardiovascular-protective effects, but large randomized clinical trials (EXAMINE [26], SAVOR-TIMI 53 [27]) reported only protection against cardiovascular events. The gene discussed is DPP4; the disease is diabetes mellitus.